Home › Research › TREM2 and immune genetics
Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome
Guimarães GR, Maklouf GR, Teixeira CE, de Oliveira Santos L, Tessarollo NG, de Toledo NE, Serain AF, de Lanna CA et al.. Nature communications, 2024-07-07
Topic: Brain proteins, microglia and lab models
Tumor-associated myeloid-derived cells (MDCs) significantly impact cancer prognosis and treatment responses due to their remarkable plasticity and tumorigenic behaviors. Here, we integrate single-cell RNA-sequencing data from different cancer types, identifying 29 MDC subpopulations within the tumor microenvironment. Our analysis reveals abnormally expanded MDC subpopulations across various tumors and distinguishes cell states that have often been grouped together, such as TREM2+ and FOLR2+ subpopulations.
Key findings
- Here, we integrate single-cell RNA-sequencing data from different cancer types, identifying 29 MDC subpopulations within the tumor microenvironment.
- Our analysis reveals abnormally expanded MDC subpopulations across various tumors and distinguishes cell states that have often been grouped together, such as TREM2+ and FOLR2+ subpopulations.
- Using deconvolution approaches, we identify five subpopulations as independent prognostic markers, including states co-expressing TREM2 and PD-1, and FOLR2 and PDL-2.
- Additionally, TREM2 alone does not reliably predict cancer prognosis, as other TREM2+ macrophages show varied associations with prognosis depending on local cues.
Why it matters
This study analyzes myeloid cell states across different cancers, not Alzheimer's disease. It identifies subpopulations linked to cancer prognosis but provides no information on treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 51/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 78 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 19.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 10.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 78 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mariana Boroni: h-index 24 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universidade de São Paulo: institution h-index 936 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38972873) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41467-024-49916-4
- PubMed: 38972873
- Original source →
- Free full text: Nature Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Guimarães, G. R., Maklouf, G. R., Teixeira, C. E., de Oliveira Santos, L., Tessarollo, N. G., de Toledo, N. E., et al. (2024). Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome. Nature communications. https://doi.org/10.1038/s41467-024-49916-4
Vancouver
Guimarães GR, Maklouf GR, Teixeira CE, de Oliveira Santos L, Tessarollo NG, de Toledo NE, et al. Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome. Nature communications. 2024. doi:10.1038/s41467-024-49916-4. PMID: 38972873.
BibTeX
@article{guimaraes2024-38972873,
author = {Guimarães, G. R. and Maklouf, G. R. and Teixeira, C. E. and de Oliveira Santos, L. and Tessarollo, N. G. and de Toledo, N. E. and Serain, A. F. and de Lanna, C. A. and others},
title = {{Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome}},
journal = {Nature communications},
year = {2024},
doi = {10.1038/s41467-024-49916-4},
pmid = {38972873},
url = {https://doi.org/10.1038/s41467-024-49916-4}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in TREM2 and immune genetics
Also in TREM2 and immune genetics
79 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.